CTKB240517C7500
- 0.15
- 0.000.00%
Cytek Biosciences Newsroom
Cytek Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
Today Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Cytek Biosciences Is Maintained at Overweight by Piper Sandler
Cytek Biosciences Is Maintained at Overweight by Piper Sandler
Cytek Biosciences Price Target Cut to $8.50/Share From $10.00 by Piper Sandler
Cytek Biosciences Price Target Cut to $8.50/Share From $10.00 by Piper Sandler
Express News | Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8.5
Cytek Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 34.92% Piper Sandler $10 → $8.5 Maintains Overweight 03/06/2024 58.73% Piper Sandler $11 → $10
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q1 2024 Earnings Conference
The following is a summary of the Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript:Financial Performance:Cytek reported a Q1 revenue of $44.9 million, up 21% year-over-year.Gross profit
Cytek Biosciences Inc (CTKB) Q1 2024 Earnings: Revenue Surges, Yet Net Loss Persists
Cytek Biosciences (CTKB) Receives a Buy From Piper Sandler
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences GAAP EPS of -$0.05, Revenue of $44.9M
Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, Vs. Street Est of $43.6M
04:49 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M
Express News | Cytek Biosciences Inc: Qtrly Shr Loss $0.05
Express News | Cytek Biosciences Inc: Reaffirms Its 2024 Revenue Guidance
Cytek Biosciences | 10-Q: Quarterly report
Express News | Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
Express News | Cytek Biosciences Reports First Quarter 2024 Financial Results
Express News | Cytek Biosciences Q1 Revenue USD 44.86 Million Vs. Ibes Estimate USD 43.6 Million
Express News | Cytek Biosciences Q1 Pretax Profit USD -8.993 Million
Express News | Cytek Biosciences Outlook FY Revenue USD 203-213 Million